Live Breaking News & Updates on Gloria biosciences

Stay informed with the latest breaking news from Gloria biosciences on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Gloria biosciences and stay connected to the pulse of your community

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

China , United-arab-emirates , Brazil , California , United-states , Canada , Israel , Australia , Foster-city , Santa-monica , Mato-grosso-do-sul , American

GILEAD AND KITE ONCOLOGY TO HIGHLIGHT BROAD AND DIVERSE ONCOLOGY PORTFOLIO AT ASCO 2024

GILEAD AND KITE ONCOLOGY TO HIGHLIGHT BROAD AND DIVERSE ONCOLOGY PORTFOLIO AT ASCO 2024
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Foster-city , California , United-states , United-kingdom , Santa-monica , China , American , Brexucabtagene-autoleucel , Axicabtagene-ciloleucel , Sacituzumab-govitecan , Sacituzumab-govitecan-hziy , European-medicines-agency

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

/PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

Israel , China , Russia , Ukraine , United-states , Russian , Gloria-biosciences , Philip-serlin , Moran-meir , John-lacey , Blackrock , Washington-university-school-of-medicine

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript March 26, 2024 BioLineRx Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Fourth Quarter and Full Year 2023 Financial […]

United-states , China , Mali , Gloria-biosciences , Phil-serlin , John-vandermosten , Columbia-university , Washington-university-school-of-medicine , Pancreatic-cancer , Washington-university-school , Kreos-capital , Lowest-fertility-rates

BioLineRx : Report of Periodic or Interim Report -March 26, 2024 at 08:26 am EDT

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE...

China , Washington , District-of-columbia , United-states , Israel , Russia , Ukraine , Modiin , Israel-general- , Russian , American , Gloria-biosciences

BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates -March 26, 2024 at 07:36 am EDT

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE...

China , Washington , District-of-columbia , United-states , Israel , Modiin , Israel-general- , Russia , Ukraine , Russian , American , States-john-lacey

BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates

- Reported significant commercial progress for APHEXDA® -- secured payer coverage representing ~95% of covered lives in the U.S.; continued progress on...

China , Israel , Russia , United-states , Ukraine , Russian , American , Moran-meir , John-lacey , Gloria-biosciences , Philip-serlin , Washington-university-school-of-medicine

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. The equity investment and collaboration amendment enable accelerated ...

China , California , United-states , Foster-city , Terry-rosen , Merdad-parsey , Johanna-mercier , Guangzhou-gloria-biosciences-co , Nasdaq , Exchange-commission , Arcus-biosciences-inc , Gilead-sciences-inc

Gilead Sciences (GILD), Arcus (RCUS) Announce Amended Collaboration and $320M Equity Investment

Gilead Sciences (GILD), Arcus (RCUS) Announce Amended Collaboration and $320M Equity Investment
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China , Terry-rosen , Merdad-parsey , Johanna-mercier , Gilead-sciences-inc , Gilead-sciences , Arcus-biosciences-inc , Astrazeneca , Nasdaq , Guangzhou-gloria-biosciences-co , Arcus-biosciences , Chief-commercial-officer

Gilead and Arcus Announce Amended Collaboration and Equity Investment

– Investment Reinforces Companies’ Conviction in TIGIT Pathway and Provides Opportunity to Accelerate the Anti-TIGIT Program –

– Additional Equity Investment of $320M, Raising Gilead’s...

Foster-city , California , United-states , China , Merdad-parsey , Terry-rosen , Johanna-mercier , Arcus-biosciences-inc , Guangzhou-gloria-biosciences-co , Astrazeneca , Gilead-sciences-inc , Exchange-commission